Nelremagpran

 

Nelremagpran

CAS 2492595-24-9

MFC15H9ClF4O3 MW 348.67 g/mol

3-[[2-Chloro-4-(trifluoromethyl)phenoxy]methyl]-2-fluorobenzoic acid

3-{[2-chloro-4-(trifluoromethyl)phenoxy]methyl}-2-fluorobenzoic acid
Mas-related G protein-coupled receptor inverse agonist, anti-inflammatory, MRGPRX4 modulator-2, BL83FAK6DZ,

Nelremagpran is an experimental drug that acts as a potent and selective antagonist (or possibly inverse agonist) of the MAS-related Gq protein-coupled receptor X4 (MRGPRX4). It has antiinflammatory effects in animal studies. This receptor is poorly characterised but is thought to be involved in immune system function, and development of selective ligands is essential for researching its role in the body.^[1][2]

Nelremagpran is an experimental drug that acts as a potent and selective antagonist or inverse agonist of the Mas-related G-protein-coupled receptor X4 (MRGPRX4). It was initially developed by Escient Pharmaceuticals, Inc. for its anti-inflammatory and anti-itch properties.

🧪 Core Mechanism

The drug targets MRGPRX4, a poorly characterized receptor found in the immune and nervous systems. It functions with high potency, exhibiting an half-maximal inhibitory concentration (IC50) of less than 100 nM.

🔬 Potential Research Applications

Because the receptor plays a significant role in mediating severe itch and pain pathways, Nelremagpran is actively used as a chemical probe to study:

• Chronic Pruritus: Conditions involving persistent, debilitating itch sensations, such as cholestatic pruritus.
• Autoimmune Diseases: Underlying mechanisms in conditions like psoriasis, multiple sclerosis, and Stevens-Johnson Syndrome.
• Inflammatory Sensation: How the body signals pain and immune hypersensitivity

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020198537&_cid=P12-MREAZN-03524-1

Synthesis of Compound 1-55

Step 4-4. Synthesis of methyl 3-(bromomethyl)-2-fluorc>benzoate (INT 4-C)

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE.........Integrated Solutions, Manufacturing Solutions, Products,
Can't Find? Let's Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

References

Identifiers
IUPAC name
CAS Number	2492595-24-9
PubChem CID	155145968
ChemSpider	115008493
UNII	BL83FAK6DZ
ChEMBL	ChEMBL4855031
Chemical and physical data
Formula	C15H9ClF4O3
Molar mass	348.68 g·mol−1
3D model (JSmol)	Interactive image
SMILES
InChI

References

1.  WO 2020/198537, Yeager A, Selfridge B, Sainz M, Martinborough E, Boehm M, Huang, "Modulators of mas-related G-protein receptor x4 and related products and methods.", published 1 October 2020, assigned to Escient Pharmaceuticals, Inc.
2.  "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 38 (4). 2024.

• Modulators of Mas-related G-protein receptor X4 and related products and methodsPublication Number: US-11840521-B2Priority Date: 2019-03-28Grant Date: 2023-12-12
• Modulators of mas-related g-protein receptor x4 and related products and methodsPublication Number: EP-3946304-A1Priority Date: 2019-03-28
• Modulators of mas-related g-protein receptor x4 and related products and methodsPublication Number: US-2023159474-A1Priority Date: 2019-03-28
• Modulators of mas-related g-protein receptor x4 and related products and methodsPublication Number: US-2023053860-A1Priority Date: 2019-03-28
• Modulators of mas-related g-protein receptor x4 and related products and methodsPublication Number: US-2021032213-A1Priority Date: 2019-03-28
• Modulators of mas-related G-protein receptor X4 and related products and methodsPublication Number: US-11643399-B2Priority Date: 2019-03-28Grant Date: 2023-05-09
• Modulators of mas-related g-protein receptor x4 and related products and methodsPublication Number: US-2024300907-A1Priority Date: 2019-03-28
• Modulators of mas-related g-protein receptor x4 and related products and methodsPublication Number: WO-2020198537-A1Priority Date: 2019-03-28
• Modulators of MAS-related G protein receptor X4 and related products and methodsPublication Number: CN-113939288-BPriority Date: 2019-03-28Grant Date: 2025-04-25

//////////nelremagpran, anax labs, Mas-related G protein-coupled receptor inverse agonist, anti-inflammatory, MRGPRX4 modulator-2, BL83FAK6DZ,

#nelremagpran, #anax labs, #Mas-related G protein-coupled receptor inverse agonist, #anti-inflammatory, #MRGPRX4 modulator-2, #BL83FAK6DZ,

NETANASVIR

 

Netanasvir

CAS 2007900-70-9

MF C51H58N8O7 MW895.1 g/mol

methyl N-[(1R)-2-[(2S,4S)-2-[5-[7-[2-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-3H-benzo[e]benzimidazol-7-yl]-2,3-dihydro-1H-inden-4-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate

• Carbamic acid, N-[(1R)-2-[(2S,4S)-2-[5-[2,3-dihydro-7-[2-[(2S,5S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-5-methyl-2-pyrrolidinyl]-1H-naphth[1,2-d]imidazol-7-yl]-1H-inden-4-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)-1-pyrrolidinyl]-2-oxo-1-phenylethyl]-, methyl ester
• Methyl ((S)-1-((2S,5S)-2-(7-(7-(2-((2S,4S)-1-((R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-4-(methoxymethyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-2,3-dihydro-1H-inden-4-yl)-1H-naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
• methyl {(2S)-1-[(12S,15S,52S,54S,7R)-7-[(methoxycarbonyl)amino]-54-(methoxymethyl)-15-methyl-6-oxo-32,33-dihydro-21H,31H,41H-2(2,7)-naphtho[1,2-d]imidazola-4(4,2)-imidazola-1(2),5(2,1)-dipyrrolidina-3(4,7)-indena-8(1)-benzenaoctaphan-11-yl]-3-methyl-1-oxobutan-2-yl}carbamate
• Methyl N-[(1R)-2-[(2S,4S)-2-[5-[2,3-dihydro-7-[2-[(2S,5S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-5-methyl-2-pyrrolidinyl]-1H-naphth[1,2-d]imidazol-7-yl]-1H-inden-4-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)-1-pyrrolidinyl]-2-oxo-1-phenylethyl]carbamate

antiviral, Dongweizhuo, HCV, Antaitavir Hasophate, HEC 74647 PA, 4Y7YD32BYY

Netanasvir (commonly prescribed as netanasvir phosphate) is a direct-acting antiviral medication primarily used to treat chronic hepatitis C virus (HCV) infection. It was approved by the China National Medical Products Administration (NMPA) under the trade name Dongweizhuo.

Key Clinical Information

• Mechanism of Action: It acts as a potent and selective NS5A inhibitor. By targeting the HCV NS5A protein, it successfully blocks viral RNA replication, virion assembly, and viral clearance mechanisms.
• Combination Therapy: It is exclusively indicated for use in combination with encofosbuvir (an NS5B polymerase inhibitor).
• Target Genotypes: The combination regimen effectively treats adult patients with chronic HCV genotypes 1, 2, 3, or 6.
• Patient Profiles: It is suitable for patients who are either treatment-naïve or have been previously treated with interferon, with or without compensated liver cirrhosis.
• Administration & Elimination: Taken orally, the drug demonstrates high metabolic stability, with feces serving as its primary elimination pathway

• OriginatorSunshine Lake Pharma
• ClassAntivirals
• Mechanism of ActionHepatitis C virus NS 5 protein inhibitors
• RegisteredHepatitis C
• 08 Feb 2025Registered for Hepatitis C (Combination therapy, Treatment-experienced) in China (PO)
• 08 Feb 2025Registered for Hepatitis C (Combination therapy, Treatment-naive) in China (PO)
• 31 Dec 2023NMPA, China accepts NDA for netanasvir for Hepatitis C for review

Netanasvir is an antiviral drug used to treat hepatitis C virus (HCV).^[1] In China, netansavir is approved for use in combination with encofosbuvir for the treatment of adult patients with chronic HCV genotypes 1, 2, 3, or 6, who are either treatment-naive or have been previously treated with interferon.^[2]

PAT

Compounds as hepatitis c virus inhibitors and pharmaceutical uses thereof

Publication Number: WO-2016141890-A1

Priority Date: 2015-03-12

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016141890&_cid=P22-MRH62L-18160-1

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE.........Integrated Solutions, Manufacturing Solutions, Products,
Can't Find? Let's Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

References

1.  "Netanasvir phosphate - Sunshine Lake Pharma". Adis Insight. Springer Nature Switzerland AG.
2.  "Netanasvir Phosphate Capsules Approved for Marketing by China NMPA". National Medical Products Administration. 2025-06-11.

Clinical data
Trade names	东卫卓; Dongweizhuo
Legal status
Legal status	Rx in China
Identifiers
IUPAC name
CAS Number	2007900-70-9
PubChem CID	122535557
UNII	4Y7YD32BYY
Chemical and physical data
Formula	C51H58N8O7
Molar mass	895.074 g·mol−1
3D model (JSmol)	Interactive image
SMILES
InChI

//////////netanasvir, anax labs,  APPROVALS 2025, CHINA 2025, antiviral, Dongweizhuo, HCV, Antaitavir Hasophate, HEC 74647 PA, 4Y7YD32BYY

#netanasvir, #anax labs,  #APPROVALS 2025, #CHINA 2025, #antiviral, #Dongweizhuo, #HCV, #Antaitavir Hasophate, #HEC 74647 PA, #4Y7YD32BYY

Olisutrigine bromide

 

Olisutrigine bromide

Cas 1393836-45-7

MF C25H35BrN2 MW443.5 g/mol

N-[2-[(2R)-1,1-dimethylpiperidin-1-ium-2-yl]ethyl]-N-(2-methylphenyl)-2,3-dihydro-1H-inden-2-amine bromide

(2R)-2-{2-[N-(2,3-dihydro-1H-inden-2-yl)-2-methylanilino]ethyl}-1,1-dimethylpiperidin-1-ium bromide
sodium channel blocker, analgesic, ASN008, ASN 008, EN 3427, 0M9Q318030

Olisutrigine bromide (also known as ASN-008 or EN3427) is an investigational, permanently charged sodium channel blocker being studied for its potent, long-lasting analgesic (pain-relieving) properties.

Key Characteristics

• Mechanism of Action: It acts as a membrane-impermeant sodium channel blocker. Because it carries a permanent cationic charge, it cannot easily cross healthy cell membranes on its own.
• Targeted Delivery: It often requires a "vehicle" or a combination drug (like lidocaine) to activate specific channels (such as TRP channels), allowing olisutrigine entry into pain-sensing neurons where it becomes entrapped and blocks pain signaling.
• Efficacy: Rodent pain models demonstrate that its analgesic effects are significantly longer-lasting than lidocaine alone.
• Chemical Profile: Its molecular formula is C₂₅H₃₅BrN₂ with a molecular weight of 443.5 g/mol, and its CAS registry number is 1393836-45-7.

Current Status

• Investigational Drug: It is not approved for human or veterinary medical use and remains in the research and development phase.
• Availability: It is strictly available as a reference standard compound for laboratory and preclinical research through chemical suppliers like MedChemExpress and BenchChem.

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

CTID: NCT05870865

Phase: Phase 2

Status: Completed

Date: 2025-05-16

SYN

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012112969&_cid=P11-MRILQZ-81481-1

Example 43: General Procedure M - Preparation of (R)-1,1 -dimethyl-2-[2-((indan-2-yl)(2-methylphenyl)amino)ethyl]piperidinium bromide

Alcohol 37b was synthesized as previouslydescribed (Tetrahedron 2007, 63, 3000-3005)

To a 250 mL round bottom flask was charged 2-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 37b (5.0 g, 21.80 mmol), dichloromethane (7.50 mL), a solution of KBr (0.52 g, 4.36 mmol) in 2.0 mL of water and TEMPO (0.1 g, 0.64 mmol). The mixture was cooled to about -5 °C. A solution of NaOCl (31.1 mL, 5.25%, 24.1 mmol) was added slowly over 20 minutes while maintaining the temperature at 0 °C. The mixture was further stirred at 0°C for 20 minutes. The organic layer was separated, and the aqueous layer was extracted with

dichloromethane. The combined dichloromethane extract was washed with water (50 mL), followed by brine. After drying over MgSO₄, the mixture was filtered and concentrated. The crude was purified with silica gel column chromatography to give product 38b (4.1 g, 83%) as colorless oil.

O

To a clean and dry 250 mL round bottom flask was charged sodium triacetoxyborohydride (5.59 g, 26.40 mmol), 4 A molecular sieves (10.0 g), amine 7e (7.37 g, 33.00 mmol) and dichloromethane (20.0 mL). The mixture was stirred and cooled to about 0 °C, and a solution of aldehyde 38b (5.0 g, 22.00 mmol) in 40 mL of dichloromethane was added. The mixture was then stirred further at 0 °C for about 1 hour and at ambient temperature for an additional 40 minutes. The reaction mixture was quenched with aqueous saturated NaHCO₃ (100 mL). After separation of organic layer, the mixture was extracted with dichloromethane. After drying over MgSO₄, the organic layer was concentrated. The crude product was purified by silica gel column chromatography to give product 40f (7.2 g, 75.3%) as colorless oil.

To a clean and dry 250 mL round bottom flask was charged lithium aluminum hydride (1.53 g, 40.27 mmol) and THF (30.0 mL). The mixture was heated to reflux. A solution of carbamate 40f (7.0 g, 16.11 mmol) in THF (40.0 mL) was added dropwise over 5 minutes. After refluxing for 15 h, the reaction mixture was cooled to 0 °C, and water (1.55 mL) was added slowly and carefully, followed by THF (100 mL) and 15% NaOH (1.55 mL). After stirring the mixture at room temperature for 1.0 h, MgSO₄ was added, and the mixture was stirred further for 15 minutes. The mixture was filtered and concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford product 11e (4.7 g, 84%) as pale yellow oil. Optical purity by chiral HPLC: 99.3% ee.

To a clean and dry 250 mL round bottom flask was charged diamine 11e (4.70 g, 13.49 mmol) and 1.07 M bromomethane in MTBE (126.0 mL, 134.8 mmol). After stirring at room temperature for 20 h, the reaction mixture was filtered. The solid cake was washed with MTBE to give the product (4.40 g, 73%) as white powder. Optical purity by chiral HPLC: 99.3% ee.

PAT

https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=53D672FEEE9931FFC5F125D61A00D7FA.wapp1nB?docId=WO2026050699&_cid=P11-MRILJW-76628-1

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025250498&_cid=P11-MRILME-78328-1

Compound 1 is described in WO2012/112969, wherein Compound 1 is reported at Example 43, and certain formulations of Compound 1 are described in WO2020/113050,

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE.........Integrated Solutions, Manufacturing Solutions, Products,
Can't Find? Let's Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

References

AMINOINDANE COMPOUNDS AND THEIR APPLICATION FOR THE TREATMENT OF PAIN

Publication Number: RU-2013142433-A

Priority Date: 2011-02-18

• Aminoindane compounds and use thereof in treating painPublication Number: US-8865741-B2Priority Date: 2011-02-18Grant Date: 2014-10-21
• Aminoindan compound and its use in treating painPublication Number: CN-107540599-BPriority Date: 2011-02-18Grant Date: 2021-06-04
• Aminoindane compounds and their use in the treatment of painPublication Number: ES-2675510-T3Priority Date: 2011-02-18Grant Date: 2018-07-11
• Aminoindane compounds and use thereof in treating painPublication Number: EP-2675787-B1Priority Date: 2011-02-18Grant Date: 2018-03-28
• AMINOINDANE COMPOUNDS AND THEIR APPLICATION FOR THE TREATMENT OF PAINPublication Number: RU-2016151688-APriority Date: 2011-02-18
• Aminoindane compounds and use thereof in treating painPublication Number: RU-2612959-C2Priority Date: 2011-02-18Grant Date: 2017-03-14
• AMINOINDAN COMPOUNDS AND USE THEREOF IN THE TREATMENT OF PAINPublication Number: DK-2675787-T3Priority Date: 2011-02-18Grant Date: 2018-07-16
• Load Aminoinden Compounds and Therapeutic Compounds Containing Them and Uses in the Treatment of Itching and PainPublication Number: IL-227967-APriority Date: 2011-02-18
• Aminoindane compounds and use thereof in treating painPublication Number: EP-3363437-B1Priority Date: 2011-02-18Grant Date: 2021-07-28
• Aminoindane compounds and use thereof in treating painPublication Number: KR-20200125765-APriority Date: 2011-02-18
• Aminoindane compounds and use thereof in treating painPublication Number: WO-2012112969-A1Priority Date: 2011-02-18
• Aminoindane compounds and use thereof in treating painPublication Number: CA-2826648-CPriority Date: 2011-02-18Grant Date: 2019-06-04
• Aminoindane compounds for use in treating urological painPublication Number: EP-3970723-A1Priority Date: 2011-02-18
• Aminoindane compounds and use thereof in treating painPublication Number: CA-2826648-A1Priority Date: 2011-02-18
• Aminoindane Compounds and Use Thereof in Treating PainPublication Number: US-2012214809-A1Priority Date: 2011-02-18
• Use of aminoindane compounds in treating overactive bladder and interstitial cystitisPublication Number: US-9044482-B2Priority Date: 2012-08-15Grant Date: 2015-06-02
• Aminoindane compounds and their use in the treatment of painPublication Number: ES-2898910-T3Priority Date: 2011-02-18Grant Date: 2022-03-09
• Aminoindane compounds and use thereof in treating painPublication Number: AU-2012219254-A1Priority Date: 2011-02-18
• Aminoindane compounds and use thereof in treating painPublication Number: EP-2675787-A1Priority Date: 2011-02-18
• Aminoindane compounds and use thereof in treating painPublication Number: EP-3363437-A1Priority Date: 2011-02-18
• 6-(4-Nitro-phenoxy)-2H-pyridazin-3-one and 6-(4-amino-phenoxy)-2H-pyridazin-3-one as intermediates of thyroid hormone analogs The preparation method of ketone derivativePublication Number: CN-116406356-APriority Date: 2020-10-23
• Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial CystitisPublication Number: US-2014051702-A1Priority Date: 2012-08-15
• Use of aminoindane compounds in treating overactive bladder and interstitial cystitisPublication Number: US-2015290182-A1Priority Date: 2012-08-15
• Use of aminoindane compounds in treating overactive bladder and interstitial cystitisPublication Number: US-9375423-B2Priority Date: 2012-08-15Grant Date: 2016-06-28
• Use of aminoindane compounds in treating overactive bladder and interstitial cystitisPublication Number: WO-2014028675-A1Priority Date: 2012-08-15

///////////olisutrigine bromide, anax labs, sodium channel blocker, analgesic, ASN008, ASN 008, EN 3427, 0M9Q318030

#olisutrigine bromide, #anax labs, #sodium channel blocker, #analgesic, #ASN008, #ASN 008, #EN 3427, #0M9Q318030

Ontunisertib

 

Ontunisertib

CAS 2647949-48-0

MFC27H21F2N5O MW469.5 g/mol

• 1H-Pyrazole-1-acetamide, N-[(2,6-difluorophenyl)methyl]-3-(6-methyl-2-pyridinyl)-4-(4-quinolinyl)-
• N-(2,6-Difluorobenzyl)-2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamide

N-[(2,6-difluorophenyl)methyl]-2-[3-(6-methyl-2-pyridinyl)-4-quinolin-4-ylpyrazol-1-yl]acetamide

N-(2,6-difluorobenzyl)-2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamide

N-[(2,6-difluorophenyl)methyl]-2-[3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl]acetamide
serine/threonine kinase inhibitor, AGMB 129, SF6HGC94LK

Ontunisertib (AGMB-129) is an experimental, orally active small-molecule drug developed by Agomab Therapeutics to treat Fibrostenosing Crohn’s Disease (FSCD). It acts as a highly selective inhibitor of ALK5 (also known as Transforming Growth Factor-beta type I receptor or TGF-β RI).

Mechanism of Action

• Local Targeting: Designed to act specifically within the gastrointestinal (GI) tract.
• High Tissue Exposure: Provides high local exposure in inflamed and scarred intestinal tissues.
• Liver Inactivation: Undergoes rapid first-pass metabolism in the liver immediately after GI absorption.
• Safety Feature: Converts into an inactive metabolite to prevent systemic exposure and avoid cardiac toxicity.

Clinical Development Status

• FDA Status: Granted Fast Track Designation by the U.S. FDA.
• Phase 2a Results: Successfully completed the STENOVA clinical trial. Results demonstrated excellent safety, high local tissue penetration, and positive structural improvements in bowel strictures.
• Phase 2b Trial: Enrolling patients for the global, 52-week NOV-ERA trial to test multiple doses against a placebo. The primary goal is assessing the endoscopically confirmed widening of narrowed intestinal strictures

• NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's DiseaseCTID: NCT07683325Phase: Phase 2Status: Not yet recruitingDate: 2026-07-06
• Human Mass Balance Study of [14C] Ontunisertib in Healthy VolunteersCTID: NCT07672574Phase: Phase 1Status: Not yet recruitingDate: 2026-06-29
• A Multiple Ascending Dose Study With AGMB-129 in Healthy ParticipantsCTID: NCT07118878Phase: Phase 1Status: CompletedDate: 2025-11-21
• STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's DiseaseCTID: NCT05843578Phase: Phase 2Status: Active, not recruitingDate: 2025-11-21
• Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy ParticipantsCTID: NCT05937386Phase: Phase 1Status: CompletedDate: 2024-06-18

SYN

• US12297186, Example 24

SYN

[WO2021105317A1]

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021105317&_cid=P20-MRPQUQ-14721-1

Example 24: N-(2,6-difluorobenzyl)-2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1 -yl)acetamide

¹H-NMR (300 MHz, DMSO-d₆): δ = 8.84 (d, J = 4.4 Hz, 1H), 8.76 (t, J = 5.3 Hz, 1H), 8.11-7.97 (m, 2H), 7.75-7.28 (m, 7H), 7.13 (t, J = 7.8 Hz, 2H), 6.97 (d, J = 7.5 Hz, 1 H), 4.99 (s, 2H), 4.43 (d, J = 5.3 Hz, 2H), 1.83 (s, 3H).

HPLC-MS: Rt 17.513 m/z 470.0 [M+H]⁺.

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025176835&_cid=P20-MRPR39-19345-1

Potent inhibitors of TGFpRII-TGFpRI (ALK5) have been described in W02021/105317 including the compound (/V-(2,6-difluorobenzyl)-2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1/7-pyrazol-1-yl)acetamide) which is the compound of formula (I) as shown below (see Example 24):

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE.........Integrated Solutions, Manufacturing Solutions, Products,
Can't Find? Let's Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

References

///////////ontunisertib, anax labs, serine/threonine kinase inhibitor, AGMB 129, SF6HGC94LK

#ontunisertib, #anax labs, #serine/threonine kinase inhibitor, #AGMB 129, #SF6HGC94LK